Infection with Mycobacterium genavense in a patient with systemic lupus erythematosus. 2009

Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
Department of Internal Medicine, Division of Nephrology, Hanover Medical School, Carl-Neuberg-Strasse 1, 30625, Hanover, Germany. J.M.Lorenzen@gmail.com

A 55-year-old woman with systemic lupus erythematosus was admitted with fever of unknown origin. She had been on an immunosuppressive regimen for the past 8 years including steroids and Azathioprine. Laboratory parameters revealed a markedly elevated C-reactive protein of 189 mg/l, antinuclear antibodies of 1:2,560, a hemoglobin level of 9.0 g/dl, and a severe lymphopenia (total lymphocytes 49.4/microl, CD4(+) cells 2/microl, CD8(+) cells 7/microl). Neither blood culture samples nor computed tomography and magnetic resonance imaging of the chest and abdomen nor a trans-esophageal echocardiography revealed positive results. A bone marrow biopsy did not show signs of hematologic disease, but revealed a small granuloma rife with acid-fast bacilli, which were later confirmed to be Mycobacterium genavense by gene sequencing. To our knowledge, this is the first case involving M. genavense infection in a patient with systemic lupus erythematosus. In contrast to other reports regarding disseminated M. genavense infection, the patient is still alive and well.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009164 Mycobacterium Infections Infections with bacteria of the genus MYCOBACTERIUM. Infections, Mycobacterium,Infection, Mycobacterium,Mycobacterium Infection
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
October 2011, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
August 2002, Journal of the Formosan Medical Association = Taiwan yi zhi,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
February 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
April 1990, Southern medical journal,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
December 2019, AIDS (London, England),
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
June 1994, The British journal of dermatology,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
March 2010, Lupus,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
February 1999, Journal of the American Academy of Dermatology,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
July 2015, Acta dermato-venereologica,
Johan Lorenzen, and Dirk Meyer-Olson, and Marion Haubitz, and Torsten Witte, and Franz Bange, and Reinhold Schmidt, and Matthias Stoll
January 1996, Clinical and experimental rheumatology,
Copied contents to your clipboard!